Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy

22 May 2023

Abstract excerpt

p53 mutation is common and highly related to radiotherapy resistance in rectal cancer. APR-246, as a small molecule, can restore the tumor-suppressor function to mutant p53. As there is currently no existing study on combining APR-246 with radiation in rectal cancer, our objective was to investigate whether APR-246 could enhance the sensitivity of colorectal cancer cells, regardless of their p53 status, to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Cancer-related Molecular Pathways
Share to Cancer Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37216282
DOI: 10.1158/1535-7163.mct-22-0275

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

APR-246 Enhances Colorectal Cancer Sensitivity to RadiotherapyPMID 37216282Read ↗

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.Semantic proximity Read ↗

APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy.Semantic proximity Read ↗

Reactivation of p53 as a radiosensitization strategy for mutant p53 cancers treated with high-LET radiotherapySemantic proximity Read ↗

Molecular Mechanisms of Synergistic Effect of PRIMA-1met and Oxaliplatin in Colorectal Cancer With Different p53 Status.Semantic proximity Read ↗

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cellsSemantic proximity Read ↗

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cellsSemantic proximity Read ↗

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.Semantic proximity Read ↗

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53Semantic proximity Read ↗

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer CellsSemantic proximity Read ↗

The Combined Anti-Tumor Effects of 5-Fluorouracil and Neurokinin Receptor Inhibitor, Aprepitant, against Colorectal Cancer: In vitro and In vivo StudySemantic proximity Read ↗

Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancerSemantic proximity Read ↗

SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.